| Model Number |
ESBF3214C103E |
| Medical Device Problem Code |
Malposition of Device (2616)
|
| Health Effect - Clinical Codes |
Obstruction/Occlusion (2422); Metabolic Acidosis (4923)
|
| Date of Event |
03/23/2026
|
|
Type of Reportable Event
|
Death
|
|
Event or Problem Description
|
|
An endurant iis stent graft system was implanted during the endovascular treatment of a 54mm abdominal aortic aneurysm.Pre-op planning showed the proximal renal diameter as 26-28mm with a short neck length of 10mm.Mild proximal calcification was noted.Moderate bilateral iliac calcification was also seen.It was reported during the index procedure, esbf3214c103e was landed at the celiac artery believing it was the renal arteries.It was fixed by doing a bilateral renal bypass and a retrograde stent of sma and the procedure was completed.The patient status post procedure was reported as alive with no injury.Per the physician the cause was due to user error.No additional clinical sequelae were reported and the patient is fine.
|
| |
|
Additional Manufacturer Narrative
|
|
Medtronic submits this report to comply with fda regulations 21 cfr parts 4 and 803.Medtronic has made reasonable efforts to provide as much relevant information as is available to the company as of the submission date of this report.This report does not constitute an admission or a conclusion by fda, medtronic, or its employees that the device, medtronic, or its employee caused or contributed to the event described in the report.Any required fields that are unpopulated are blank because the information is currently unknown or unavailable.Medtronic will submit a supplemental report if additional relevant information becomes known.
|
| |
|
Additional Manufacturer Narrative
|
|
Additional information received: it was reported one day post the index procedure, the patient became acidotic.The patient's family decided to withdraw care and the patient expired one day post the index procedure.Medtronic submits this report to comply with fda regulations 21 cfr parts 4 and 803.Medtronic has made reasonable efforts to provide as much relevant information as is available to the company as of the submission date of this report.This report does not constitute an admission or a conclusion by fda, medtronic, or its employees that the device, medtronic, or its employee caused or contributed to the event described in the report.Any required fields that are unpopulated are blank because the information is currently unknown or unavailable.Medtronic will submit a supplemental report if additional relevant information becomes known.
|
| |
|
Additional Manufacturer Narrative
|
|
Correction: the correct aware date for additional information submitted for patient death associated with report # 9612164-2026-01521, 001 s 25-mar-2026.Medtronic submits this report to comply with fda regulations 21 cfr parts 4 and 803.Medtronic has made reasonable efforts to provide as much relevant information as is available to the company as of the submission date of this report.This report does not constitute an admission or a conclusion by fda, medtronic, or its employees that the device, medtronic, or its employee caused or contributed to the event described in the report.Any required fields that are unpopulated are blank because the information is currently unknown or unavailable.Medtronic will submit a supplemental report if additional relevant information becomes known.
|
| |
|
Additional Manufacturer Narrative
|
|
Additional information received: it was reported that the relationship of the reported acidosis and death are considered to be due to device placement.Medtronic submits this report to comply with fda regulations 21 cfr parts 4 and 803.Medtronic has made reasonable efforts to provide as much relevant information as is available to the company as of the submission date of this report.This report does not constitute an admission or a conclusion by fda, medtronic, or its employees that the device, medtronic, or its employee caused or contributed to the event described in the report.Any required fields that are unpopulated are blank because the information is currently unknown or unavailable.Medtronic will submit a supplemental report if additional relevant information becomes known.
|
| |
|
Additional Manufacturer Narrative
|
|
Medtronic submits this report to comply with fda regulations 21 cfr parts 4 and 803.Medtronic has made reasonable efforts to provide as much relevant information as is available to the company as of the submission date of this report.This report does not constitute an admission or a conclusion by fda, medtronic, or its employees that the device, medtronic, or its employee caused or contributed to the event described in the report.Any required fields that are unpopulated are blank because the information is currently unknown or unavailable.Medtronic will submit a supplemental report if additional relevant information becomes known.
|
| |
|
Search Alerts/Recalls
|